| Authors: |
de Jong A; VetPath Study Group, c/o CEESA, 1, Rue Defacqz, Brussels, Belgium; Bayer HealthCare AG, Animal Health GmbH, Leverkusen, Germany. Electronic address: anno.jong@bayer.com., Thomas V; VetPath Study Group, c/o CEESA, 1, Rue Defacqz, Brussels, Belgium; MSD Animal Health, Schwabenheim, Germany., Simjee S; VetPath Study Group, c/o CEESA, 1, Rue Defacqz, Brussels, Belgium; Elanco Animal health, Basingstoke, UK., Moyaert H; VetPath Study Group, c/o CEESA, 1, Rue Defacqz, Brussels, Belgium; Zoetis, Zaventem, Belgium., El Garch F; VetPath Study Group, c/o CEESA, 1, Rue Defacqz, Brussels, Belgium; Vétoquinol S.A., Lure, France., Maher K; Quotient Bioresearch, Fordham, UK., Morrissey I; Quotient Bioresearch, Fordham, UK., Butty P; VetPath Study Group, c/o CEESA, 1, Rue Defacqz, Brussels, Belgium; Ceva Santé Animale, Libourne, France., Klein U; VetPath Study Group, c/o CEESA, 1, Rue Defacqz, Brussels, Belgium; Novartis Animal Health, Basel, Switzerland., Marion H; VetPath Study Group, c/o CEESA, 1, Rue Defacqz, Brussels, Belgium; European Animal Health Study Centre (CEESA), Brussels, Belgium., Rigaut D; VetPath Study Group, c/o CEESA, 1, Rue Defacqz, Brussels, Belgium; Virbac S.A., Carros, France., Vallé M; VetPath Study Group, c/o CEESA, 1, Rue Defacqz, Brussels, Belgium; AM Consultant, Saint Bénigne, France. |